References
- Stas SN, Anastasiadis AG, Fisch H, Benson MC, Shabsigh R. Urologic aspects of andropause. Urology. 2003; 61(2): 261–266.
- Chen H. Kleinfelter's Syndrome. E-medicine Web site. http://www.emedicine.com/ped/topic1252.htm. Updated July 31, 2007. Accessed September 21, 2008.
- Mahmoud A, Comhaire FH. Mechanisms of disease: late-onset hypogonadism. Nat Clin Pract Urol. 2006; 3(8): 430–438.
- The Endocrine Society. Summary from the Second Annual Andropause Consensus Meeting. Beverly Hills, CA: Highwire Press; 2001; 1–5.
- Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60(7): 762–769.
- Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004; 350(5): 482–492.
- McLaughlin SP, Shaban SF, Carson CC. Androgen deficiency in the aging male. In: Kirby RS, Carson CC III, Kirby MG, et al, eds. Men's Health. New York, NY: Taylor and Francis; 2004.
- Heinemann LA. Aging Males' Symptoms scale: a standardized instrument for the practice. J Endocrinol Invest. 2005; 28(11 suppl proceedings): 34–38.
- Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000; 49(9): 1239–1242.
- Heaton JP. Hormone treatments and preventative strategies in the aging male: whom and when to treat? Rev Urol. 2003; 5(suppl 1): 16–21.
- Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002; 87(2): 589–598.
- Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004; 172(3): 920–922.
- Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age matched normal controls. Clin Endocrinol. 1994; 40(3): 341–349.
- Anderson RA, Wallace BM, Wu FC. Effects of testosterone enanthate on serum lipoproteins in man. Contraception. 1995; 52(2): 115–119.
- Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001; 111(4): 261–269.
- Kapoor D, Goodwin E, Channer KS, et al. Testoterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J of Endocrinol. 2006; 154(6): 899–906.
- Matsumoto AM, Sandblom RE, Schuene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives and sleep. Clin Endocrinol. 1985; 22(6): 713–721.
- Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab. 2005; 90(7): 3989–3994.
- Vermeulen A. Androgen replacement therapy in the aging male—a critical evaluation. J Clin Endocrinol Metab. 2001; 86(6): 2380–2390.
- Carson CC, Kirby RS, Goldstein I, eds. Textbook of Erectile Dysfunction. Oxford, England: Isis Medical Media; 1999.
- Pope HG, Kouri EM, Hudson JL. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry. 2000; 57(2): 133–140.
- Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry. 1999; 45(3): 254–260.
- Liverman CT, Blazer DG, eds. Testosterone and Aging: Clinical Research Directions. Institute of Medicine, The National Academics. Washington, DC: National Academy Press; 2004.